Gold bars to be exempt from tariffs, White House clarifies
Investing.com - Xeris Pharmaceuticals (NASDAQ: XERS) reported second quarter EPS of $-0.010, $0.02 better than the analyst estimate of $-0.030. Revenue for the quarter came in at $71.54M versus the consensus estimate of $63.96M.
Guidance
Xeris Pharmaceuticals sees FY 2025 revenue of $280.000M-$290.000M versus the analyst consensus of $269.400M.
Xeris Pharmaceuticals’s stock price closed at $5.49. It is up 9.580% in the last 3 months and up 146.190% in the last 12 months.
Xeris Pharmaceuticals saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Xeris Pharmaceuticals’s stock price’s past reactions to earnings here.
According to InvestingPro, Xeris Pharmaceuticals’s Financial Health score is "great performance".
Check out Xeris Pharmaceuticals’s recent earnings performance, and Xeris Pharmaceuticals’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar